Overview
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Eligibility
Inclusion Criteria:
- HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
Exclusion Criteria:
- TNBC breast cancer
- Hormone receptor positive breast cancer
- Non-available FFPE samples
- Treated except T-Dxd